Actions
Pages
Subscribe for newsletter
Stories
Rwanda is set to obtain a portion of carbon credits instead of a portion of profits derived from Article 6 of the Paris Agreement. These credits will be applied to offset the country's National Determined Contributions (NDC) climate commitments. This initiative will contribute to advancing the industry, enabling Rwanda to diminish its climate footprint by facilitating access to cleaner technology through reduced emissions.
Rwanda’s decision to prioritize carbon credits over short-term gains sets an example for other nations. Emphasizing the importance of transparency and quality in its carbon market framework, Rwanda ensures that purchased credits meet international standards. The country aims to offer high-quality carbon credits that provide climate benefits, empower communities, and protect biodiversity, underlining integrity in the voluntary market.
Rwanda's ambitious Green Growth and Climate Resilience Strategy requires an estimated $11 billion investment, a significant challenge considering the current inflows of aid and investment.
Story
Chinese EV makers and battery manufacturers are targeting overseas production, particularly in Southeast Asia, to tap into growing markets and meet local demands.
There is increasing demand for EVs in Southeast Asia driven by government policies such as Malaysia's National Automotive Policy 2020 and commitment to achieving net-zero GHGs by 2050; and the Thai government’s target for 50% of vehicle output to be battery-powered by 2030.
It also helps that Neta is incredibly popular in Thailand, with the brand being the best-selling EV in the country this year.
The anticipated mass delivery of SE Asia-produced EVs and batteries in 2024 will likely catalyze further Chinese investments. Analysts have noted that establishing local production capabilities allows companies to expedite product launches and develop offerings more attuned to local market needs.
Story
AstraZeneca inks a $247 million deal with AI biotech firm Absci to develop innovative cancer-fighting antibodies, aiming to transform oncology treatment and patient outcomes.
The role of AI in drug discovery, particularly in oncology, is reshaping timelines and methodologies, promising more rapid and precise development of cancer treatments. The AstraZeneca and Absci collaboration could greatly improve cancer treatment success, particularly in lung cancer where early detection increases 5-year survival rates from 10% up to 92%.
“AI is enabling us to not only increase the success and speed of our biologics discovery process, but also enhance the diversity of the biologics we discover,” said AstraZeneca Senior Vice President Puja Sapra.
The partnership's future hinges on the successful integration of Absci's AI in AstraZeneca's oncology pipeline.
Story
Innovators
Scroll
Open
Close